Bei Qing Selected Research

Neoplasms (Cancer)

1/2022	DNA Damage Response Gene-Based Subtypes Associated With Clinical Outcomes in Early-Stage Lung Adenocarcinoma.
10/2019	[Tumor infiltrating T lymphocyte components in malignant pleural effusion of lung adenocarcinoma and their killing activities to autologous tumor cells].
1/2019	ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bei Qing Research Topics

Disease

3	Neoplasms (Cancer) 01/2022 - 01/2019
2	Adenocarcinoma of Lung 01/2022 - 01/2019
2	Acute Lung Injury 12/2021 - 11/2021
2	Lung Neoplasms (Lung Cancer) 12/2021 - 01/2019
1	Carcinogenesis 12/2021
1	Dyspnea (Shortness of Breath) 10/2021
1	Infections 10/2021
1	Fever (Fevers) 10/2021
1	Malignant Pleural Effusion 10/2019
1	Neoplasm Metastasis (Metastasis) 01/2019

Drug/Important Bio-Agent (IBA)

2	HMGB2 ProteinIBA 12/2021 - 11/2021
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Pharmaceutical PreparationsIBA 12/2021
1	Tumor Biomarkers (Tumor Markers)IBA 12/2021
1	VaccinesIBA 12/2021
1	Biomarkers (Surrogate Marker)IBA 12/2021
1	Biological ProductsIBA 01/2019
1	Messenger RNA (mRNA)IBA 01/2019
1	Cisplatin (Platino)FDA LinkGeneric 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019

Therapy/Procedure

1	Therapeutics 12/2021
1	Lung Transplantation 10/2021
1	Intramuscular Injections 10/2019
1	Immunotherapy 10/2019